<DOC>
	<DOCNO>NCT02696642</DOCNO>
	<brief_summary>To characterize safety , tolerability , pharmacokinetics immunogenicity anetumab ravtansine subject advance solid cancer different degree hepatic renal impairment</brief_summary>
	<brief_title>Phase I Study Anetumab Ravtansine Hepatic Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Male female subject age ≥18 year Histologically cytologically confirm , locally advanced metastatic solid cancer know express mesothelin tumor cell surface ( e.g . predominantly epithelial [ &gt; =50 % tumor component ] pleural peritoneal mesothelioma , epithelial ovarian cancer [ include fallopian tube primary peritoneal ] , adenocarcinoma pancreas , triplenegative adenocarcinoma breast , nonsmallcell adenocarcinoma lung , endometrial cancer , serous uterine cancer , gastric cancer [ include gastroesophageal junction ] , colon cancer , cholangiocarcinoma , thymic carcinoma , etc. ) . Subjects resect primary cancer document metastasis local recurrence eligible . Subjects must standard therapy available , actively refuse standard therapy Subjects must meet criterion one 4 treatment group : Group A : Adequate hepatic renal function ( control ) Group B : Mild hepatic impairment , i.e . Grade A accord ChildPugh Classification ( total score 5 6 ) adequate renal function Group C : Moderate hepatic impairment , i.e . Grade B accord ChildPugh Classification ( total score 7 , 8 9 ) adequate renal function Group D : Moderate renal impairment , i.e . eGFR ( estimate glomerular filtration rate ) &lt; 60 ≥30 mL/min per 1.73 m2 hepatic function well , equal mild impairment accord ChildPugh Classification ( total score ≤6 ) Adequate bone marrow function Life expectancy least 12 week ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 ( control mild hepatic impairment group ) , 02 ( moderate hepatic impairment moderate renal impairment group ) Previous concurrent cancer distinct primary site histology cancer evaluate study , except cervical carcinoma situ , treat basal cell carcinoma , superficial noninvasive bladder tumor previous cancer curatively treat &gt; 3 year start anetumab ravtansine New progressive brain meningeal spinal metastasis Gilbert 's syndrome benign congenital hyperbilirubinemia benign congenital hyperbilirubinemia eligible mild moderate hepatic impairment moderate renal impairment group . CTCAE ( Common Terminology Criteria Adverse Events ) Grade ≥2 bleed within 4 week start anetumab ravtansine Uncontrolled cardiovascular disease hypertension . QTc interval &gt; 480 m , heart rate ≥100 bpm ≤45 bpm , LVEF ( leave ventricular ejection fraction ) &lt; 50 % Corneal epitheliopathy eye disorder may predispose subject druginduced corneal epitheliopathy Systemic anticancer therapy ( except topical intracavitary treatment negligible absorption systemic circulation ) within 4 week start anetumab ravtansine , within 5 halflives anticancer agent start anetumab ravtansine , whichever longer . Mitomycin C nitrosoureas must exclude within 6 week start anetumab ravtansine . Radiotherapy within 4 week start anetumab ravtansine Use drug know renal hepatic toxicity within 2 week start anetumab ravtansine EoT ( end treatment ) visit Use strong cytochrome P450 3A4 ( CYP3A4 ) inhibitor strong CYP3A4 inducer within 2 week start anetumab ravtansine EoT visit Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mesothelin-expressing advance solid cancer</keyword>
</DOC>